The payouts and the pipeline of claims
Authorities in Denmark have compensated 31 patients with a total of DKK 15 million, roughly $2.2 million, after they developed a rare eye condition following use of Novo Nordisk's weight-loss treatments. Claims run through Danish Patient Compensation, an independent group funded by the state and insurers.
Ninety-four people who believe they experienced the side effect after using Wegovy or Ozempic have submitted claims. Of those, 29 were declined and 34 await decisions. Denmark, a country of about 6 million people, started awarding compensation for NAION cases last year.
Safety scrutiny and company response
Novo Nordisk and Eli Lilly are under heightened scrutiny over a potential side effect that can cause permanent vision loss. In 2024, Denmark's medicines regulator was the first to alert European authorities to a possible link, making the country an early test case.
US regulators have acted too. Doctors have said patients should be told about the possible risk.
When headlines raise questions about risks and rules, sign up for the free Market Briefs newsletter for a quick daily update
Novo Nordisk says it does not see a cause-and-effect relationship between its medicines and the eye condition, while acknowledging the impact on patients and families. "We remain confident in the benefit-risk profile of our GLP-1 medicines," a spokesperson said by email.
How Denmark structures compensation
Payments come from the Danish state, not from Novo. Because Denmark's public health system covers most medical treatment, awards generally emphasize harms like diminished earning capacity and lasting injury rather than hospital expenses.
NAION occurs when reduced blood flow injures the optic nerve. It is rare, most often affects people over 50, cannot be treated, does not reverse, and can lead to blindness.
What this means for your portfolio
For GLP-1 makers, the direction of risk is on the label and in the headlines. Watch how the 34 pending Danish cases are resolved and whether other regulators mirror the FDA's class-wide warning, since that can influence demand, litigation exposure, and long-run margins for both Novo Nordisk and Eli Lilly.
Good decisions start with clear context, so get the free Market Briefs in your inbox for a short daily take
